The hypereosinophilic syndromes: still more heterogeneity.

@article{Gleich2005TheHS,
  title={The hypereosinophilic syndromes: still more heterogeneity.},
  author={Gerald J. Gleich and Kristin M. Leiferman},
  journal={Current opinion in immunology},
  year={2005},
  volume={17 6},
  pages={679-84}
}
In 1968, the term hypereosinophilic syndromes (HES) was coined to refer to a spectrum of eosinophil-associated diseases presumed to be caused by an underlying immunological pathology. In the 1990s, the identification of an HES subset with T lymphocyte clonality and production of cytokines, particularly IL-5, validated this concept. Then, in 2002, imatinib mesylate, which was introduced for the treatment of chronic myelogenous leukemia, effectively controlled another subgroup of HES patients… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Similar Papers

Loading similar papers…